Didanosine once daily

Potential for expanded use

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Factors affecting patient adherence to therapy, such as frequent daily dosing and complex dosing schedules, are widely understood to be key obstacles to the durability of effective anti-HIV therapy. Didanosine, a nucleoside analogue reverse transcriptase inhibitor (NRTI) that is a core component of combination antiretroviral regimens, is currently indicated for twice-daily dosing. However, the active metabolite of didanosine (2',3'-dideoxyadenosine-5'-triphosphate) has a long intracellular haft-life that supports the use of didanosine in a more patient-friendly, once-daily dosing schedule. Clinical studies in which didanosine was administered either once or twice daily, as monotherapy or in combination with another NRTI, have demonstrated the equivalence of both dosing schedules, with respect to safety and tolerability, virologic and immunologic endpoints, and short-term clinical effects (e.g., weight gain). Preliminary results from recent studies support the clinical efficacy and utility of once-daily didanasine in combination antiretroviral regimens that provide maximal drug exposure, while allowing for once- or twice-daily dosing of all component drugs. (C) 2000 Lippincott Williams and Wilkins.

Original languageEnglish (US)
Pages (from-to)2421-2428
Number of pages8
JournalAIDS
Volume14
Issue number16
DOIs
StatePublished - 2000
Externally publishedYes

Fingerprint

Didanosine
Appointments and Schedules
Reverse Transcriptase Inhibitors
Nucleosides
Patient Compliance
Pharmaceutical Preparations
Weight Gain
HIV
Safety
Therapeutics
2',3'-dideoxyadenosine triphosphate

Keywords

  • Antiretroviral therapy
  • Combination therapy
  • Didanosine
  • Dosing

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Cite this

Didanosine once daily : Potential for expanded use. / Pollard, Richard B.

In: AIDS, Vol. 14, No. 16, 2000, p. 2421-2428.

Research output: Contribution to journalArticle

Pollard, Richard B. / Didanosine once daily : Potential for expanded use. In: AIDS. 2000 ; Vol. 14, No. 16. pp. 2421-2428.
@article{6057ee927f1043d08f69563f6705964e,
title = "Didanosine once daily: Potential for expanded use",
abstract = "Factors affecting patient adherence to therapy, such as frequent daily dosing and complex dosing schedules, are widely understood to be key obstacles to the durability of effective anti-HIV therapy. Didanosine, a nucleoside analogue reverse transcriptase inhibitor (NRTI) that is a core component of combination antiretroviral regimens, is currently indicated for twice-daily dosing. However, the active metabolite of didanosine (2',3'-dideoxyadenosine-5'-triphosphate) has a long intracellular haft-life that supports the use of didanosine in a more patient-friendly, once-daily dosing schedule. Clinical studies in which didanosine was administered either once or twice daily, as monotherapy or in combination with another NRTI, have demonstrated the equivalence of both dosing schedules, with respect to safety and tolerability, virologic and immunologic endpoints, and short-term clinical effects (e.g., weight gain). Preliminary results from recent studies support the clinical efficacy and utility of once-daily didanasine in combination antiretroviral regimens that provide maximal drug exposure, while allowing for once- or twice-daily dosing of all component drugs. (C) 2000 Lippincott Williams and Wilkins.",
keywords = "Antiretroviral therapy, Combination therapy, Didanosine, Dosing",
author = "Pollard, {Richard B}",
year = "2000",
doi = "10.1097/00002030-200011100-00002",
language = "English (US)",
volume = "14",
pages = "2421--2428",
journal = "AIDS",
issn = "0269-9370",
publisher = "Lippincott Williams and Wilkins",
number = "16",

}

TY - JOUR

T1 - Didanosine once daily

T2 - Potential for expanded use

AU - Pollard, Richard B

PY - 2000

Y1 - 2000

N2 - Factors affecting patient adherence to therapy, such as frequent daily dosing and complex dosing schedules, are widely understood to be key obstacles to the durability of effective anti-HIV therapy. Didanosine, a nucleoside analogue reverse transcriptase inhibitor (NRTI) that is a core component of combination antiretroviral regimens, is currently indicated for twice-daily dosing. However, the active metabolite of didanosine (2',3'-dideoxyadenosine-5'-triphosphate) has a long intracellular haft-life that supports the use of didanosine in a more patient-friendly, once-daily dosing schedule. Clinical studies in which didanosine was administered either once or twice daily, as monotherapy or in combination with another NRTI, have demonstrated the equivalence of both dosing schedules, with respect to safety and tolerability, virologic and immunologic endpoints, and short-term clinical effects (e.g., weight gain). Preliminary results from recent studies support the clinical efficacy and utility of once-daily didanasine in combination antiretroviral regimens that provide maximal drug exposure, while allowing for once- or twice-daily dosing of all component drugs. (C) 2000 Lippincott Williams and Wilkins.

AB - Factors affecting patient adherence to therapy, such as frequent daily dosing and complex dosing schedules, are widely understood to be key obstacles to the durability of effective anti-HIV therapy. Didanosine, a nucleoside analogue reverse transcriptase inhibitor (NRTI) that is a core component of combination antiretroviral regimens, is currently indicated for twice-daily dosing. However, the active metabolite of didanosine (2',3'-dideoxyadenosine-5'-triphosphate) has a long intracellular haft-life that supports the use of didanosine in a more patient-friendly, once-daily dosing schedule. Clinical studies in which didanosine was administered either once or twice daily, as monotherapy or in combination with another NRTI, have demonstrated the equivalence of both dosing schedules, with respect to safety and tolerability, virologic and immunologic endpoints, and short-term clinical effects (e.g., weight gain). Preliminary results from recent studies support the clinical efficacy and utility of once-daily didanasine in combination antiretroviral regimens that provide maximal drug exposure, while allowing for once- or twice-daily dosing of all component drugs. (C) 2000 Lippincott Williams and Wilkins.

KW - Antiretroviral therapy

KW - Combination therapy

KW - Didanosine

KW - Dosing

UR - http://www.scopus.com/inward/record.url?scp=0033739807&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033739807&partnerID=8YFLogxK

U2 - 10.1097/00002030-200011100-00002

DO - 10.1097/00002030-200011100-00002

M3 - Article

VL - 14

SP - 2421

EP - 2428

JO - AIDS

JF - AIDS

SN - 0269-9370

IS - 16

ER -